OpenAlex
PricingAboutJobs
Log inGet started
Work

Omalizumab and the risk of malignancy: Results from a pooled analysis

HTML

Year: 2012
Type: article
Source: Journal of Allergy and Clinical Immunology
DOI: 10.1016/j.jaci.2012.01.033
Authors: William Busse, Roland Buhl, Carlos Fernandez Vidaurre, Martin Blogg, Jin Zhu, Mark D. Eisner, Janice Canvin
Institutions: University of Wisconsin–Madison, University of Wisconsin Health, Johannes Gutenberg University Mainz, University Medical Center of the Johannes Gutenberg University Mainz, Novartis (United States), Genentech
Language: English

Topic: Pharmacovigilance and Adverse Drug Reactions
Subfield: Toxicology
Field: Pharmacology, Toxicology and Pharmaceutics
Domain: Life Sciences
Keywords: omalizumab, cancer risk, anti-IgE therapy, drug safety, pooled clinical trial data, rate ratios
SDG: Good health and well-being

Open Access status: closed

Funders: Novartis, Genentech
OpenAlex ID: W1988223366
FWCI: 13.51
Cites: 62
Cited by: 178
Related to: 10
OpenAlex
Nonprofit
Open DataOpen Data
Open Source
Product
Search
Compare
Pricing
Repositories
Unpaywall
Unsub
Developers
API docs
Data snapshot
Status
Source code
Organization
About
Team
Testimonials
Brand
Jobs
Community
Help center
Contact
Events
Blog
Mailing list
Supporters
Legal
Privacy
Accessibility
Terms